LEADER 09859nam 2200397 450 001 9910583376803321 005 20230120002710.0 010 $a0-08-101925-4 035 $a(CKB)4100000000864060 035 $a(EXLCZ)994100000000864060 100 $a20180305d2018 uy 0 101 0 $aeng 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aIron oxide nanoparticles for biomedical applications $esynthesis, functionalization and application /$fedited by Morteza Mahmoudi, Sophie Laurent 210 $aAmsterdam $cElsevier$d2018 215 $axvii, 315 p. $cill. ;$d23 cm 225 0 $aMetal oxides series 320 $aIncludes bibliographical references and index. 327 $aMachine generated contents note:$g1.$tMetal Oxide Particles and Their Prospects for Applications --$g1.1.$tMagnetic Metal Oxides /$rS. Laurent /$rS. Boutry /$rR.N. Muller --$g1.2.$tMetal Oxides With Photoluminescence Properties /$rS. Laurent /$rS. Boutry /$rR.N. Muller --$g1.3.$tMetal Oxides in Electronics, Catalysis, Gas Sensors and Energy Technologies /$rS. Laurent /$rS. Boutry /$rR.N. Muller --$g1.4.$tMetal Oxides in Biomedical Applications /$rS. Laurent /$rS. Boutry /$rR.N. Muller --$tReferences /$rS. Laurent /$rS. Boutry /$rR.N. Muller --$tFurther Reading /$rS. Laurent /$rS. Boutry /$rR.N. Muller --$g2.$tIron Oxide Nanoparticles for Biomedical Applications: Synthesis, Functionalization, and Application /$rS. Laurent /$rS. Boutry /$rR.N. Muller --$g2.1.$tIron Nanoparticles: Advantages and Limitations for Biomedical Applications /$rG. Cotin /$rS. Piant /$rD. Mertz /$rD. Felder-Flesch /$rS. Begin-Colin --$g2.2.$tSynthesis of Iron Oxide Nanoparticles Aimed for Biomedical Applications /$rG. Cotin /$rS. Piant /$rD. Mertz /$rD. Felder-Flesch /$rS. Begin-Colin --$g2.3.$tStabilization of the Nanosystems /$rG. Cotin /$rS. Piant /$rD. Mertz /$rD. Felder-Flesch /$rS. Begin-Colin --$g2.4.$tMethods of IONPs Functionalization for Biomedical Applications /$rG. Cotin /$rS. Piant /$rD. Mertz /$rD. Felder-Flesch /$rS. Begin-Colin --$tReferences /$rG. Cotin /$rS. Piant /$rD. Mertz /$rD. Felder-Flesch /$rS. Begin-Colin --$g3.$tProtein Corona: The Challenge at the Nanobiointerfaces /$rG. Cotin /$rS. Piant /$rD. Mertz /$rD. Felder-Flesch /$rS. Begin-Colin --$g3.1.$tIntroduction /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rR. Spitler --$g3.2.$tThe Protein Corona /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rR. Spitler --$g3.3.$t"Hard" Versus "Soft" Corona /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rR. Spitler --$g3.4.$tReversible Versus Irreversible Interactions Between NPs and Proteins /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rR. Spitler --$tReferences /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rR. Spitler --$g4.$tNanocytotoxicity /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rR. Spitler --$g4.1.$tIntroduction /$rS. Zanganeh /$rR. Spitler /$rM. Erfanzadeh /$rJ.Q. Ho /$rM. Aieneravaie --$g4.2.$tCytotoxicity /$rS. Zanganeh /$rR. Spitler /$rM. Erfanzadeh /$rJ.Q. Ho /$rM. Aieneravaie --$g4.3.$tSuperparamagnetic Iron Oxide Nanoparticles /$rS. Zanganeh /$rR. Spitler /$rM. Erfanzadeh /$rJ.Q. Ho /$rM. Aieneravaie --$tReferences /$rS. Zanganeh /$rR. Spitler /$rM. Erfanzadeh /$rJ.Q. Ho /$rM. Aieneravaie --$g5.$tMagnetic Particle Imaging (MPI) /$rS. Zanganeh /$rR. Spitler /$rM. Erfanzadeh /$rJ.Q. Ho /$rM. Aieneravaie --$g5.1.$tIntroduction /$rS. Zanganeh /$rM. Aieneravaie /$rM. Erfanzadeh /$rJ.Q. Ho /$rR. Spitler --$g5.2.$tSuperparamagnetic Iron Oxide Nanoparticles for MPI /$rS. Zanganeh /$rM. Aieneravaie /$rM. Erfanzadeh /$rJ.Q. Ho /$rR. Spitler --$g5.3.$tSize and Homogeneity /$rS. Zanganeh /$rM. Aieneravaie /$rM. Erfanzadeh /$rJ.Q. Ho /$rR. Spitler --$g5.4.$tIron Oxide Nanoparticle Coatings /$rS. Zanganeh /$rM. Aieneravaie /$rM. Erfanzadeh /$rJ.Q. Ho /$rR. Spitler --$tReferences /$rS. Zanganeh /$rM. Aieneravaie /$rM. Erfanzadeh /$rJ.Q. Ho /$rR. Spitler --$g6.$tTargeted Iron Oxide (Nano)particles Used as MRI Contrast Agent in Small Animal Models /$rS. Zanganeh /$rM. Aieneravaie /$rM. Erfanzadeh /$rJ.Q. Ho /$rR. Spitler --$g6.1.$tIntroduction /$rS. Boutry /$rR.N. Muller /$rS. Laurent --$g6.2.$tMRI of Apoptosis With Iron Oxide-Based Compounds /$rR.N. Muller /$rS. Laurent /$rS. Boutry --$g6.3.$tMRI of Inflammatory Diseases With Iron Oxide-Based Compounds /$rS. Boutry /$rR.N. Muller /$rS. Laurent --$g6.4.$tMRI of Tumor Angiogenesis With Iron Oxide-Based Compounds /$rS. Boutry /$rR.N. Muller /$rS. Laurent --$tReferences /$rS. Boutry /$rR.N. Muller /$rS. Laurent --$g7.$tDual-Modality Imaging /$rS. Boutry /$rR.N. Muller /$rS. Laurent --$g7.1.$tThe Necessity of Dual Modality Imaging /$rA. Lahooti /$rS. Shanehsazzadeh /$rS. Laurent --$g7.2.$tMolecular Imaging /$rA. Lahooti /$rS. Shanehsazzadeh /$rS. Laurent --$g7.3.$tMultimodality Imaging /$rA. Lahooti /$rS. Shanehsazzadeh /$rS. Laurent --$g7.4.$tPET/MRI /$rA. Lahooti /$rS. Shanehsazzadeh /$rS. Laurent --$g7.5.$tAdvantages /$rA. Lahooti /$rS. Shanehsazzadeh /$rS. Laurent --$g7.6.$tChallenges in PET/MRI /$rA. Lahooti /$rS. Shanehsazzadeh /$rS. Laurent --$tReferences /$rA. Lahooti /$rS. Shanehsazzadeh /$rS. Laurent --$g8.$tCurrent Outlook and Perspectives on Nanoparticle-Mediated Magnetic Hyperthermia /$rS. Laurent /$rS. Shanehsazzadeh /$rA. Lahooti --$g8.1.$tHistorical Development and Outlook /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$g8.2.$tRationalization of NP Characteristics for MH /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$g8.3.$tInterparticle Interactions /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$g8.4.$tJustification for the Use of Iron Oxides in Magnetic Hyperthermia /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$g8.5.$tOther Materials Used and Envisioned for Magnetic Hyperthermia /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$g8.6.$tOverview on the Current Instrumentation Available /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$g8.7.$tClinical Trials (Past, Present, and Future Ones) /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$g8.8.$tOther Selected Topics in Magnetic Hyperthermia Research /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$g8.9.$tConclusions and Prospects /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$tAcknowledgments /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$tReferences /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$g9.$tDrug Delivery /$rC. Blanco-Andujar /$rF.J. Teran /$rD. Ortega --$g9.1.$tIntroduction /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$g9.2.$tIron Oxide Nanoparticles: Design Considerations /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$g9.3.$tIn Vivo Barriers /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler /$rS. Zanganeh /$rJ.Q. Ho --$g9.4.$tPhysicochemical Considerations /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$g9.5.$tHydrodynamic Size /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$g9.6.$tShape /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$g9.7.$tSurface Properties /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$g9.8.$tDirecting Nanoparticles In Vivo /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$g9.9.$tDrug Loading and Release /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$g9.10.$tToxicity /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$g9.11.$tCoating of SPIONs /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$tReferences /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$g10.$tTumor-Targeted Therapy /$rS. Zanganeh /$rJ.Q. Ho /$rM. Aieneravaie /$rM. Erfanzadeh /$rM. Pauliah /$rR. Spitler --$g10.1.$tIntroduction /$rM. Pauliah /$rS. Zanganeh /$rM. Erfanzadeh /$rJ.Q. Ho --$g10.2.$tNanotechnology and Cancer Therapy /$rM. Pauliah /$rS. Zanganeh /$rM. Erfanzadeh /$rJ.Q. Ho --$g10.3.$tIron Oxide Nanoparticles and Cancer Therapy /$rM. Pauliah /$rS. Zanganeh /$rM. Erfanzadeh /$rJ.Q. Ho --$g10.4.$tConclusion /$rM. Pauliah /$rS. Zanganeh /$rM. Erfanzadeh /$rJ.Q. Ho --$tReferences /$rM. Pauliah /$rS. Zanganeh /$rM. Erfanzadeh /$rJ.Q. Ho --$g11.$tCancer Therapy /$rM. Pauliah /$rS. Zanganeh /$rM. Erfanzadeh /$rJ.Q. Ho --$g11.1.$tIntroduction /$rS. Zanganeh /$rJ.Q. Ho /$rR. Spitler /$rT. Jafari /$rM. Erfanzadeh /$rM. Pauliah /$rN. Khakpash --$g11.2.$tThe Role of Magnetic Iron Oxide in Cancer Therapy /$rS. Zanganeh /$rJ.Q. Ho /$rR. Spitler /$rT. Jafari /$rN. Khakpash /$rM. Erfanzadeh /$rM. Pauliah --$g11.3.$tDiagnostic Imaging and Cancer Therapy /$rS. Zanganeh /$rJ.Q. Ho /$rR. Spitler /$rT. Jafari /$rN. Khakpash /$rM. Erfanzadeh /$rM. Pauliah --$g11.4.$tConclusion /$rS. Zanganeh /$rJ.Q. Ho /$rR. Spitler /$rT. Jafari /$rN. Khakpash /$rM. Erfanzadeh /$rM. Pauliah --$tReferences /$rS. Zanganeh /$rJ.Q. Ho /$rR. Spitler /$rT. Jafari /$rN. Khakpash /$rM. Erfanzadeh /$rM. Pauliah. 606 $aBiomedical engineering 606 $aNanoparticles$xMagnetic properties 606 $aIron oxides$xMagnetic properties 615 0$aBiomedical engineering. 615 0$aNanoparticles$xMagnetic properties. 615 0$aIron oxides$xMagnetic properties. 676 $a610.28 701 $aMahmoudi$b Morteza$f1979-$0911397 701 $aLaurent$b Sophie$f1967-$0969270 801 0$b241008 801 1$b241008 906 $aBOOK 912 $a9910583376803321 996 $aIron oxide nanoparticles for biomedical applications$92202448 997 $aUNINA